RAB27B and chronic myelogenous leukemia, BCR-ABL1 positive: To verify whether the drug resistance of CML cells was associated with RAB27B-mediated drug transport, K562/G01 cells transfected with Sh-NC or sh-RAB27B were treated with 2 μmol/L imatinib for 48 h, and then cells were incubated in culture medium with no imatinib for another 24 h.